key: cord-0703607-6n0nzzmd
authors: Candon, Sophie; Guerrot, Dominique; Drouot, Laurent; Lemoine, Mathilde; Lebourg, Ludivine; Hanoy, Mélanie; Boyer, Olivier; Bertrand, Dominique
title: T cell and antibody responses to SARS‐CoV‐2: Experience from a French transplantation and hemodialysis center during the COVID‐19 pandemic
date: 2020-11-06
journal: Am J Transplant
DOI: 10.1111/ajt.16348
sha: d7032d6b912670098a28db3e3f1420bafb10299c
doc_id: 703607
cord_uid: 6n0nzzmd

Immunosuppressed organ‐transplanted patients are considered at risk for severe forms of COVID‐19. Moreover, exaggerated innate and adaptive immune responses might be involved in severe progression of the disease. However, no data on the immune response to SARS‐CoV‐2 in transplanted patients are currently available. Here, we report the first assessment of antibody and T cell responses to SARS‐CoV‐2 in 11 kidney‐transplanted patients recovered from RT‐PCR–confirmed (n = 5) or initially suspected (n = 6) COVID‐19. After reduction of immunosuppressive therapy, RT‐PCR–confirmed COVID‐19 transplant patients were able to mount vigorous antiviral T cell and antibody responses, as efficiently as two nontherapeutically immunosuppressed COVID‐19 patients on hemodialysis. By contrast, six RT‐PCR–negative patients displayed no antibody response. Among them, three showed very low numbers of SARS‐CoV‐2–reactive T cells, whereas no T cell response was detected in the other three, potentially ruling out COVID‐19 diagnosis. Low levels of T cell reactivity to SARS‐CoV‐2 were also detected in seronegative healthy controls without known exposure to the virus. These results suggest that during COVID‐19, monitoring both T cell and serological immunity might be helpful for the differential diagnosis of COVID‐19 but are also needed to evaluate a potential role of antiviral T cells in the development of severe forms of the disease.

During the course of coronavirus disease 2019 (COVID- 19) , both the humoral and cellular arms of the adaptive immune system are required for viral clearance and resolution of the infection, as well as possibly for protection against a second SARS-CoV-2 infection. 1 It has been suggested that exaggerated innate and adaptive immune responses might be involved in the severe progression of the disease occurring in 15% of cases, leading to severe distress respiratory syndrome and/or multiple organ failure. 2, 3 Immunosuppressed patients such as transplanted patients have been considered at risk for severe forms of the disease. 4 Here, we report the first assessment of the cellular and humoral immune response to SARS-CoV-2 in 11 kidney-transplanted patients and two patients on hemodialysis awaiting a kidney transplant, recovering or recovered from a SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR)confirmed (n = 5) or initially suspected (n = 6) COVID-19 infection.

We show that after tapering of therapeutic immunosuppression, confirmed COVID-19 transplant patients were able to mount vigorous antiviral-specific T cell and antibody responses, as efficiently as patients on hemodialysis. By contrast, SARS-CoV-2-PCR-negative patients displayed no antibody response and no or very few specific T cells. Finally, low levels of T cell reactivity to SARS-CoV-2 antigens were detected in seronegative healthy controls with no known exposure to the virus during the study period.

All subjects were recruited between April 14, 2020 and May 28, 2020. Eleven kidney-transplanted patients were included in the study, including five patients diagnosed with SARS-CoV-2 RT-PCR-confirmed COVID-19, six patients suspected of COVID-19 based on suggestive symptomatology (n = 5) or typical pulmonary radiological imaging (n = 1), and two patients on hemodialysis awaiting a kidney transplant and diagnosed with RT-PCR-confirmed COVID-19. Blood samplings were performed close to or after their recovery, except in one patient still hospitalized for post-COVID-19 pulmonary functional impairment. In addition, 31 healthy donors were included in the study during the same period.

None of them had a known exposure to SARS-CoV-2 during the epidemic and were not RT-PCR tested. All subjects provided informed and written consent.

A multiplex addressable laser bead immunoassays (ALBIA) was designed for the detection of IgG and IgM targeting the S1 subunit of S protein as well as IgG specific for the N protein. Sensitivity of these assays was, respectively, >97%, 75%, and 100% at >13 days postsymptom onset (Drouot et al, manuscript in preparation). Specificity was ≥98% for all three parameters.

Peripheral blood mononuclear cells were isolated by density gradient centrifugation of blood samples and used immediately. PBMCs (in concentrations adjusted to 2x10 5 CD3 + T cells per well) were plated in anti-IFNγ-coated Elispot 96-well plate in presence of overlapping 15-mer peptide pools spanning the sequence of SARS-CoV-2 structural and nonstructural proteins: S (pool S1 spanning the N-terminal part of the protein including the S1-subunit, and pool S2 spanning the C-terminal part), N, M, E, NS3A, NS7A, NS8, NS9B

(JPT, Strassberg, Germany). Negative and positive control stimulation, medium only, and phytohemagglutinin, respectively, were included in the assay. After an overnight culture, cells were washed and captured IFNγ was revealed using a colorimetric assay (UCytech, Utrecht, The Netherlands). Spots were counted with an automated ELISPOT reader (AID, Strassberg, Germany). For each stimulation condition, the average spot number observed in wells without antigen was subtracted. Results were expressed as spot forming cells (SFC) per 10 6 CD3 + T cells. For each assay, a specific response was considered positive if SFC number was superior to 3 standard deviations of spot numbers observed in wells without antigens (ranging between 9 and 20 SFC/10 6 CD3 + T cells).

Between February and April 2020, six kidney-transplanted patients were diagnosed with COVID-19 based on a positive SARS-CoV-2 RT-PCR on a nasopharyngeal swab (n = 5, KTX1-5) or typical pulmonary radiological imaging (n = 1, KTX6; Table 1 ). All of them were hospitalized. Four (KTX1, 2, 3, and 5) experienced a severe course of the disease, requiring intensive care with mechanical ventilation in one case ( Table 2) . Five of them presented with lymphopenia ranging 190 to 730 lymphocytes/mm 3 (Table 3) .

Immunosuppressive therapy was reduced in all six cases, with withdrawal of mycophenolate acid (n = 6), calcineurin inhibitors (n = 4), or belatacept (n = 1) ( Table 2) . Steroids were maintained at 20 mg per day in all patients including KTX6. All patients but one recovered and were discharged from hospital on 26 ± 12 (mean±standard deviation [SD]) days after symptom onset with reintroduction of the previous immunosuppressive regimen shortly before or on the day of hospital discharge (Table 2) . A single patient (KTX3) was still hospitalized in intensive care unit (ICU) more than 80 days after symptom onset, due to post-COVID-19 pulmonary function impairment, without reintroduction of immunosuppressive therapy and no impact on kidney graft function to date. Five additional transplanted patients (KTX7-11) reported mild symptoms compatible with COVID-19. SARS-CoV-2 RT-PCR testing was negative in all of them. Only one displayed significant lymphopenia (KTX9). The patients who remained suspected of COVID-19 were cared for as confined outpatients. Their immunosuppressive therapy was unchanged and they recovered rapidly without complications. Two patients on hemodialysis awaiting a kidney transplant and followed in our center were also diagnosed with COVID-19 based on PCR testing. One of them was hospitalized for dyspnea that retroceded rapidly allowing for hospital discharge a week later.

We assessed the immune response to SARS-CoV-2 in these 13 patients (seven RT-PCR positive and six RT-PCR-negative) close to and/or after their recovery, except in one patient (KTX3) who was still in the ICU (Table 2 ). Using a multiplex ALBIA serological assay, we found that all seven patients with RT-PCR-confirmed COVID-19 displayed SARS-CoV-2 antibodies ( Figure 1A ) 21 to 42 days after symptom onset (mean ± SD: 33 ± 8 days): IgG reactive to the N protein was detected in all seven cases; IgG reactive to the S1 subunit was detected in five cases while S1 IgM was found in only three patients. In three cases (KTX1, KTX5, and HD1), testing was repeated 17 to 28 days later showing a decrease in anti-S1 (n = 2) and anti-N (n = 3) IgG titers ( Figure 1B ). There was a trend toward a negative correlation between N IgG titer and time from symptom onset.

In the six transplanted patients with negative RT-PCR, no SARS-CoV-2-specific antibodies could be detected, thus potentially ruling out COVID-19 diagnosis. None of the 31 healthy controls, except one, showed significant titers of SARS-CoV-2 antibodies.

We then evaluated the T cell response to nine structural and nonstructural SARS-CoV-2 peptide pools using an IFNγ ELISPOT assay ( Figure 2A ). All seven PCR-confirmed COVID-19 patients, transplanted or on hemodialysis, displayed IFNγ-producing T cells reactive to at least six of the nine peptide pools, 17 to 42 days postsymptom onset (mean ± SD: 28 ± 10 days). Total numbers of SARS-CoV-2-reactive T cells were high (mean ± SD: 3911 ± 2837 SFC/10 6 CD3 + T cells; Table 3 ). Responses to S (pool S1 and S2), N, M, and accessory protein ORF3A were dominant (mean ± SD: 948 ± 770; 946 ± 727; 616 ± 725, 663 ± 713; and 449 ± 536 SFC/10 6 CD3 + T cells for S1, S2, N, M, and ORF3A, respectively). T cells reactive to structural protein E and accessory proteins ORF7A, ORF8, and ORF9B were less numerous (mean ± SD: 18 ± 29; 140 ± 107; 84 ± 142; and 45 ± 23 SFC/10 6 CD3 + T cells, respectively). Overall, SARS-CoV-2-reactive T cells represented on average 0.4% ± 0.3% of total CD3 + T cells or, taking into account CD3+ T cell counts, moderately low in six of seven patients, 5.0 ± 7.3 specific cells/mm 3 ( Table 3 ). The level of responses did not significantly differ between transplanted patients and those on hemodialysis. No correlation between time since symptom onset and number of T cells reactive was evidenced ( Figure S1 ). However, in KTX1, the number of T cells reactive to S1, S2, N, and M decreased significantly (at least 2 fold) when tested 22 days later, after hospital discharge and reintroduction of a full immunosuppressive regimen ( Figure S1 ).

By contrast, among patients with negative SARS-CoV-2 RT-PCR (KTX-6-11) suspected of COVID-19, three did not show any SARS-CoV-2-reactive T cells, including patient KTX6 who displayed pulmonary radiological imaging strongly suggestive of SARS-CoV-2 pneumonia. One patient (KTX7) displayed low numbers (≤35 SFC/10 6 CD3 + T cells) of T cells producing IFNγ in response to S2, N, and M while two others (KTX9 and KTX10) showed a weak response to S2 only (≤30 SFC/10 6 CD3 + T cells). Similar reactivity profiles were observed among healthy controls with no known exposure to SARS-CoV-2: few T cells (≤35 SFC/10 6 CD3 + T cells) reactive to S2 only, S2 plus one or two other proteins or a single non-S2 structural or accessory protein were detected in 29.0%, 12.9%, and 29.0% of the cases, respectively. Of note, in the single healthy donor with a low titer of anti-N IgG, no SARS-CoV-2 T cell reactivity was detected. Overall,

and healthy controls showed similar low total number of T cells reactive to three or less SARS-CoV-2 peptide pools (mean ± SD: 21 ± 29 and 21 ± 19 SFC/10 6 CD3 + T cells, respectively, P > .05). To explore a possible T cell cross-reactivity toward common coronavirus and SARS-CoV-2, we evaluated the response to the S protein of Figure 2B ).

(S1 plus S2 pools) were observed in these three groups of patients 

We present here the first report of assessment of the humoral and cellular immune response to SARS-CoV-2 in kidney transplant recipients recovering or recovered from COVID-19 after reduction of immunosuppressive therapy. In patients with RT-PCR-confirmed COVID-19, transplanted or on hemodialysis, significant titers of anti-S1 and anti-N IgGs were observed from day 26 to day 53 following symptom onset. Anti-N IgGs were detected in all six tested patients and anti-S1 IgGs in five of them. Anti-S1 IgMs were found in three patients only. These results are in line with several reports

showing that anti-SARS-CoV-2 IgG antibodies can be first detected between 7 and 14 days after symptom onset and that they persist following virus clearance. 5 Surprisingly, we found in two recovered transplanted patients (severe disease course) and one patient on hemodialysis (moderate severity), who could be tested again 2 to 4 weeks after the first sampling, a sharp decrease in anti-S1 or anti-N IgG titers that still remained detectable. Based on the knowledge regarding the kinetics of the immune response to SARS-CoV-1 and MERS-CoV, it is expected that antibody responses to SARS-CoV-2 might wane slowly and persist up to 60 weeks after symptom onset. [5] [6] [7] In a recent retrospective study in COVID-19 kidney-transplanted patients in whom immunosuppressive regimen was withdrawn or reduced, IgG antibodies to SARS-CoV-2 N and S proteins were maintained at stable titers up to 59 days following infection, independently of disease severity. 8 In patients with several samplings, only the first ones are plotted. B, Numbers of T cells reactive to S1 and S2 peptide pools representative of the S protein of HCoV-229E (E-S1 and E-S2) and HCoV-OC43 (O-S1 and O-S2) in four RT-PCR-positive transplanted patients, six RT-PCR negative transplanted patients, and 15 healthy controls regimen was systematically reduced at diagnosis, showed similar amplitude and reactivity profile of SARS-CoV-2 T cell response than the two patients on hemodialysis. We did not observe a significant correlation between SARS-CoV-2-reactive T cell numbers and antibody titers in patients with confirmed COVID-19 (data not shown).

Noteworthily, the two patients (KTX1 and KTX5) in whom a sharp decrease in SARS-CoV-2 antibody titers (S1 and/or N IgGs) was observed between two samplings (day 38-60 and day 39-56, respectively) did not show any significant change in their S-or N-specific T cell numbers. This may reflect differential kinetics of the humoral and cellular responses, with a faster decline in antibody titers 9,10 as compared to the rate of contraction of T cell numbers that can be expected following viral clearance.

The role of numerous and diverse anti-SARS-CoV-2 T cell responses, such as those evidenced here, in the severity of the disease could not be addressed due to the limited size of our study. Such T cell response may well contribute to severe progression of the disease through cytokine production and tissular immunopathology. A recent study found however no significant difference in the numbers of IFNγ-producing T cells in response to S, M, or N peptide pools between patients convalescent from mild or severe disease. 17 In our study, the frequencies of SARS-CoV-2-specific T cells were in fact in the same range as those observed in convalescent patients from predominantly mild 13, 18 or severe COVID-19. 11 Using a cytometry-based assay, low frequencies of CD4 + T cells, responding almost exclusively to the same S2 peptide pool as the one used in our study, were found in 34% of seronegative healthy donors (n = 68). 12 CoV-2 epitopes (derived from the C-terminal end of S, or from N and nonstructural proteins) and showed that 24% of them were in fact also reactive to analogous epitopes from HCoVs, that in some cases were better antigens than the corresponding SARS-CoV-2

peptides. 25 Such results support the speculation that preexisting cross-reactive T cells to HCoVs could impact infection outcome in case of exposure to SARS-CoV-2, and potentially afford some level of protection as observed for influenza virus H1N1. However, as in RT-PCR-negative transplanted patients, we cannot rule out that in some of our healthy controls who were recruited during the pandemic, low numbers of SARS-CoV-2-specific T cells may have been induced through exposure to SARS-CoV-2 in absence of overt symptomatology and detectable antibody responses, as described in SARS-CoV-2-exposed family members and 2020 blood donors. 17 Overall, we show that following reduction of immunosuppressive therapy, kidney-transplanted patients with severe COVID-19

are able to mount vigorous T cell and antibody responses to SARS-CoV-2, that are detectable up to 60 days following symptom onset.

The ability of fully immunosuppressed transplanted patients to mount T cell and antibody responses to SARS-CoV-2 remains however to be determined. Assessment of T cell immunity together with humoral immunity may be helpful for differential diagnosis of COVID-19 in case of negative SARS-CoV-2 RT-PCR testing. In addition, low levels of T cell reactivity to SARS-CoV-2 can be observed in seronegative patients and healthy controls, that may arise from T cell cross-reactivity to endemic HCoVs or alternatively from unknown exposure to SARS-CoV-2. Further longitudinal studies will be necessary to determine the early and long-term kinetics of T cell and antibody responses as well as the role of T cells in the progression of the disease.

The authors wish to thank the health-care professionals of the 

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

COVID-19 infection: the perspectives on immune responses

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Associate Editors ftEET. Early experience with COVID-19 in kidney transplantation

Immunology of COVID-19: Current State of the Science

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv

In-depth virological assessment of kidney transplant recipients with COVID-19

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals

Clinical and immunological features of very long-term survivors with a single renal transplant

Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

SARS-CoV2 Testing. The Limit of Detection Matters

Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use

Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion. medRxiv

COVID-19 infection in kidney transplant recipients

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans